New research suggests that individuals who come off new GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who end traditional diet and exercise programs.
Research printed in a leading health publication shows that while obese people can lose substantial amounts of their body weight while using the jabs, the weight comes back at an estimated rate of nearly a kilo each month after stopping.
"People buying these treatments must be aware of the potential of fast rebound weight gain when the therapy is stopped," warns expert Dr. Susan Jebb.
Such speed of recovery implies a return to starting mass in about one and a half years.
Comparing Approaches
The research, which examined 37 of studies involving over 9,000 of participants, contrasted the results of GLP-1 agonists with older methods.
Researchers point out that individuals who shed pounds through diet and exercise typically have a less rapid creep back—around 0.1 kg a month—once they finish.
Understanding the Fast Rebound
Experts suggest the mode of action of the injections is key to understanding the amplified rebound.
GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Long-term administration of GLP-1 concentrations far above than the body's typical production might result in the body to generate a reduced amount of its endogenous GLP-1, and may also diminish responsiveness to its actions," said Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this medication results in appetite is uncontrolled, making binge eating far more likely."
A Lifelong Disease?
The NHS suggest the injections for individuals with obesity-related medical conditions, accompanied by recommended lifestyle changes.
Professionals say that, due to the significant potential of relapse, the therapy should be considered ongoing.
This view is echoed by drug manufacturers, who say that the results "emphasize the chronic character of obesity," akin to managing conditions like high blood pressure.
User Testimonies
People who have stopped the medication describe a intense resurgence of cravings.
"It felt as if a trigger that goes on and I was suddenly starving," described an individual.
This challenge is compounded if patients have not developed lasting lifestyle or habit changes during therapy.
Growing Use
Survey data indicate that a significant number of adults in the UK have tried these injections in the last 12 months, with interest being substantial.
- Use is greater among women than men.
- The middle-aged age group shows the greatest level of interest.
- Many obtain the drugs through private prescriptions rather than the NHS.
In conclusion, experts caution that while these medications are effective agents for weight loss, they are not a standalone fix and long-term success hinges on combined lifestyle support.
